Loading...
XLONOBI
Market cap43mUSD
Dec 24, Last price  
8.50GBP
1D
0.00%
1Q
23.55%
IPO
-85.34%
Name

Ondine Biomedical Inc

Chart & Performance

D1W1MN
XLON:OBI chart
P/E
—
P/S
5,138.39
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.26%
Rev. gr., 5y
26.39%
Revenues
1m
+88.56%
00001,619,2091,605,485912,3261,030,2311,532,838412,000373,000464,0001,791,0002,569,000638,0001,203,000
Net income
-14m
L-30.66%
-73,290-1,537,483-84,343-8,539,069-11,963,096-13,154,325-10,269,721-4,595,474-3,256,795-6,434,000-16,656,000-14,164,000-16,917,000-82,816,000-20,784,000-14,412,000
CFO
-14m
L-16.47%
-49,50125,261-66,204-8,386,839-10,844,066-11,904,485-8,928,676-3,438,721-2,720,118-5,268,000-10,084,000-7,551,000-6,331,000-12,540,000-16,345,000-13,653,000

Profile

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
URL
https://ondinebio.com/
IPO date
Dec 06, 2021
Employees
18
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
1,203
88.56%
638
-75.17%
2,569
43.44%
Cost of revenue
15,438
18,941
19,631
Unusual Expense (Income)
NOPBT
(14,235)
(18,303)
(17,062)
NOPBT Margin
Operating Taxes
1,412
32,731
Tax Rate
NOPAT
(14,235)
(19,715)
(49,793)
Net income
(14,412)
-30.66%
(20,784)
-74.90%
(82,816)
389.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,912
36,928
BB yield
Debt
Debt current
382
359
645
Long-term debt
700
1,433
336
Deferred revenue
Other long-term liabilities
481
467
Net debt
(1,899)
(11,333)
(29,384)
Cash flow
Cash from operating activities
(13,653)
(16,345)
(12,540)
CAPEX
(177)
(311)
(77)
Cash from investing activities
(177)
(311)
(77)
Cash from financing activities
3,785
(275)
41,904
FCF
(13,780)
(20,518)
(53,105)
Balance
Cash
2,981
13,125
30,365
Long term investments
Excess cash
2,921
13,093
30,237
Stockholders' equity
(26,687)
(16,880)
2,493
Invested Capital
29,313
29,901
28,370
ROIC
ROCE
EV
Common stock shares outstanding
197,112
194,588
79,638
Price
Market cap
EV
EBITDA
(13,648)
(17,810)
(16,548)
EV/EBITDA
Interest
38
30
1,199
Interest/NOPBT